Treatment of postmenopausal women with low doses of estradiol-17, (1 mg/d) and dl-norgestrel (0.75 mg/d) significantly reduced fasting serum levels of low density lipoprotein (LDL) cholesterol and lowered very low density lipoprotein (VLDL) triglycerides in four of five subjects. To explain these results, the kinetics of VLDL and LDL apolipoprotein (apo) B turnover were studied by injecting autologous '25I-labeled VLDL and 13"I-labeled LDL into subjects before discontinuing longterm (4-yr) treatment with the estradiol-17,8 and dl-norgestrel and again 7 wk after stopping treatment. The 24% mean decrease in VLDL apo B pool size during treatment was associated with a significant increase in VLDL apo B fractional catabolic rate (15±1 vs. 11±1 pools/d), whereas production rate was similar to control (24±3 vs. 21±2 mg/kg per d). There was a significant 25% mean decrease in LDL apo B pool size (27±2 vs. 36±3 mg/kg) due to a significant decrease in total (8.3±0.3 vs. 11±1 mg/kg per d) and independent (3.3±0.5 vs. 6.6±0.8 mg/kg per d, P < 0.05) LDL apo B production. Estradiol-17,6 together with dl-norgestrel lowered plasma VLDL by enhancing their clearance and LDL by reducing their production.
Introduction
Currently 90% of women survive to reach the menopause, including over 30 million American women with an average postmenopausal life expectancy of 28 years (1) . When ovarian secretion of estradiol and progesterone ceases (2) , the concentration of serum cholesterol rises (3, 4) , and women lose their relative immunity, as compared with men, from coronary artery disease (5) . Simultaneously, the incidences of bone fractures associated with osteoporosis (6) and of deaths from female cancers rise sharply (7) . Heart attacks and underlying coronary artery disease become major causes of death and disability, causing four times as many deaths among women as cancer of the breast and endometrium combined (8) . Retrospective studies suggest that estrogens could possibly halve the risk of death from ischemic heart disease in postmenopausal women (9) .
Although high doses of estrogen alone increase serum triglycerides (10), Wolfe and Plunkett have reported that treatment with combined low doses of estradiol-1 7, and dl-norgestrel significantly lowers both serum triglyceride and cholesterol levels in postmenopausal women (1 1). 18 subjects receiving this regimen for 3 yr had an average reduction of fasting serum total cholesterol of 19%, low density lipoprotein (LDL)' cholesterol of 23%, total triglycerides of 31%, and very low density lipoprotein (VLDL) triglycerides of 31% (P < 0.025); these were associated with a favorable decrease of 14% in the ratio of LDL cholesterol: high density lipoprotein cholesterol (Plunkett, E. R., and B. M. Wolfe, unpublished observations). The effects of these low doses of estradiol-1 7# and dl-norgestrel on the kinetics of apolipoprotein (apo) B metabolism of plasma VLDL and LDL of postmenopausal women are the subject of this report.
Methods
Subjects. Five participants were recruited from University Hospital outpatient clinics (Table I) . Each experienced typical menopausal symptoms and was amenorrheic for at least 6 mo (serum follicle-stimulating hormone > 70 U/liter) before starting hormonal replacement therapy with estradiol-1 71 (1 mg/d, 25 of 28 d) and dl-norgestrel (0.75 mg/d, 28 of 28 d) 4 yr earlier. Fasting serum cholesterol and triglyceride concentrations exceeded the 95th percentile in two subjects (1 1), and cholesterol concentration alone was elevated in one subject before treatment. At the end of the 4-yr period of therapy with estradiol-17j3 and dl-norgestrel five subjects volunteered for studies ofthe kinetics of VLDL-and LDL apo B turnover. Each subject underwent a turnover study immediately before discontinuing the medication and again 7 wk after stopping the medication and completing the first study. During the present study the subjects were maintained on conventional diets containing -15% protein, 45% carbohydrate, and 40% fat (< 500 mg cholesterol/d). They were admitted to the hospital and given low-fat diets (< 5 g fat/d, 62 g protein, and 378 g carbohydrate consisting of 2% milk fat cottage cheese, cereals, juices, gelatin, and skim milk) during the first day of each of their turnover experiments. Subjects received no other medications known to affect lipid metabolism, and intake of ethanol was < 30 ml/d for the month before each turnover study. All (12, 16) . VLDL were washed once by recentrifugation. Apo B was isolated from each lipoprotein fraction by isopropanol precipitation and its specific activity determined (17). Analyses. As in rats receiving d-norgestrel alone (15), the specific activity curves of VLDL apo B were better described by a three-pool than a two-pool model (Fig. 1) . The kinetic parameters of the threepool model for '25I-VLDL apo B were calculated using a correction (15) of the method of Goodman et al. (18) according to Skinner (19) . However, there was little difference between the three-pool and twopool models for the decay of radioactivity in '3'I-LDL apo B, and both yielded curves that were similar to the observed values ( Fig. 1) . Thus, the specific activity curves of LDL apo B were analyzed and kinetic parameters calculated using the conventional two-pool model of Gurpide et al. (12, (20) (21) (22) Zilversmit (23) . The percent of LDL apo B that was not derived from IDL apo B was calculated as: 1 -(area under the 1251_ LDL apo B specific activity curve/area under the '251-IDL apo B specific activity curve) X 100 (14, 24) . Concentrations of cholesterol and triglycerides in the chloroform-methanol extract of plasma were determined as previously described (13) . Variation in lipoprotein, apo B, and lipid concentrations and kinetics between control and treatment periods were assessed using the paired t test (25) .
Results
Treatment with the combined estradiol-1 7f3 and dl-norgestrel consistently lowered serum cholesterol and decreased fasting triglycerides in four of the five subjects (Table I) . These changes were associated with corresponding alterations in the concentrations of lipids in VLDL, IDL, and LDL (Table II) . (Table III) .
Values for the kinetic parameters of LDL turnover calculated from the '311-labeled LDL apo B decay curves using the two-pool model of Gurpide et al. (20) (21) (22) Examination of precursor-product relationships (23) between lipoprotein fractions indicated that VLDL were the sole precursors of IDL. As illustrated in a representative subject (Fig. 2) , the decay curves of VLDL apo B consistently intersected those of IDL apo B at their peaks during both treatment and control. However, the LDL apo B specific activity curves consistently reached their peaks before they were intersected by their corresponding IDL curves. This is consistent with the view that not all LDL were derived from IDL catabolism (23) . Comparisons of the areas under the specific activity curve as described by Goldberg et al. (24) Little is known about the mechanisms of the interactions of estrogens and progestins on lipoprotein metabolism in women. Our findings in female rats do not completely parallel those in the human subjects (27) , suggesting that intact rats may respond differently than postmenopausal women. Although estradiol abolished d-norgestrel inhibition of triglyceride synthesis in rat hepatocytes and antagonized the hypolipemic effect of d-norgestrel in intact female rats, d-norgestrel failed to reduce the serum triglyceride-elevating effects of estradiol (27) . However, in these estrogen-deficient postmenopausal subjects, we found that serum triglycerides fell in four of five subjects during treatment with the combined hormones (Table I) .
Studies in rats also indicated that d-norgestrel inhibited hepatic synthesis and release of VLDL triglycerides (28), in part by inhibition of the glycerol-3-phosphate acyltransferase (EC .2.3.1.15) step in hepatic triglyceride synthesis (29) . However, VLDL apo B production in d-norgestrel-treated rats was not affected ( 15) , consistent with the secretion of VLDL particles that contain less triglyceride. Plunkett and Wolfe have previously reported that in a larger group of postmenopausal women combined low doses of estradiol-17, and dl-norgestrel significantly lowered serum triglycerides (1 1) . VLDL-triglycerides fell in four of five subjects during treatment in the present study (Table II) . Taken together with the unchanged rates of production of VLDL apo B, these observations suggest that VLDL particles may have contained less triglyceride on the average during the treatment vs. the control period. Increased hepatic triglyceride lipase activity resulting from norgestrel administration (30) could also play a role in lowering VLDL and IDL levels by enhancing their removal from the plasma (31) .
The decreased pool size of LDL apo B and the lower LDL cholesterol concentrations in the present study are explained by the observed reduction in LDL apo B production (Table  IV) . In previous studies, in rats treated with d-norgestrel alone, LDL pool size increased due to a decrease in fractional catabolic rate, whereas LDL apo B production was unchanged.
The present observations in postmenopausal women receiving both estradiol-17(3 and dl-norgestrel suggest that estradiol may neutralize the inhibitory properties of d-norgestrel on LDL apo B catabolism.
The molecular basis for the suppression of LDL apo B production by combined low doses of estrogen and progestin observed in the present study is unknown. There has been a paucity of studies of VLDL and LDL turnover in postmenopausal women. The present studies indicate that a substantial fraction ofthe LDL apo B secreted in postmenopausal women lacking estrogen and progesterone is produced via either a direct synthesis pathway (14, 24) or a very rapid pathway of conversion of VLDL to LDL that cannot be detected. Nevertheless, this pathway is suppressible by exogenous estrogen and progestin. We are unaware of previous studies of this pathway of LDL apo B metabolism in premenopausal women, so it cannot be determined at this time whether low-dose estradiol-17(3 and dl-norgestrel restore the pattern of LDL apo B metabolism in postmenopausal to that of premenopausal women. However, Reardon et al. have reported a study in a postmenopausal Type III subject in whom a dose of estrogen (0.75 mg piperazine estrone sulphate/d) comparable to the present dose, had no effect on VLDL apo B production, but lowered IDL apo B production by one-third through abolition of the direct pathway of IDL apo B synthesis (32).
Drastic reductions of plasma LDL concentrations have been reported in rats receiving very large pharmacological doses of ethinyl estradiol; however, these changes in LDL concentration have been related to increases in the number of hepatic receptors for LDL (33) . We found no evidence of increased LDL receptor activity during treatment since the FCR of LDL apo B remained unchanged.
A previous study of one premenopausal woman receiving a dose ofestrogen (ethinyl estradiol, 100 ,g/d) that was about an order ofmagnitude higher in potency (26) than was used in the present study, detected no significant change in LDL apo B production, nor any significant reduction in the plasma con-centration of LDL protein, which reflects mainly apo B (10). Thus, the reductions in LDL apo B pool size and production rate in the present study were most likely mediated by the combined interactions of the estradiol-1 7,3 and dl-norgestrel. We conclude that the favorable decreases in VLDL and LDL concentrations observed with this combined estrogen and progestin regimen reflect enhanced VLDL clearance and significantly reduced LDL production. These observations may be ofclinical importance in the hormonal management of postmenopausal and other women with primary ovarian failure, especially with respect to the prevention ofatherosclerosis (8, 11) .
